Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20276029 | 0.85 | CA2 (0.41) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL460485 | 0.76 | CYP1A2 (0.36) | CA2GABRA1GABRB2ALDH1A1KDM4E | |
| SCHEMBL13495858 | 0.76 | AKR1B1 (0.44) | AKR1B1CA12CA9ALDH1A1TDP1 | |
| SCHEMBL29692994 | 0.74 | GABBR2 (0.43) | CA2CA12CA9 | |
| SCHEMBL25523060 | 0.74 | SMN1; SMN2 (0.38) | CA2ALDH1A1TDP1 | |
| SCHEMBL502464 | 0.74 | GABBR2 (0.43) | CA2CA12CA9 | |
| SCHEMBL24503584 | 0.73 | CA2 (0.32) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL5539477 | 0.73 | AKR1B1 (0.45) | AKR1B1CA12CA9ALDH1A1TSHR | |
| SCHEMBL5539483 | 0.72 | MEN1 (0.47) | AKR1B1CA12CA9ALDH1A1TSHR | |
| SCHEMBL32672943 | 0.72 | AKR1B1 (0.44) | AKR1B1CA12CA9ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117370-A1 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2023-04-20 | — | — | US | disclosed |
| US-20170015645-A1 | SUBSTITUTED PYRAN DERIVATIVES | UNIV WAYNE STATE (US) | 2017-01-19 | — | — | US | disclosed |
| US-20140309427-A1 | Substituted Pyran Derivatives | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-16 | — | — | US | disclosed |
| US-6743923-B2 | A BENZYLIDENE DERIVATIVES USED FOR OSTEOCLAST FORMATION INHIBITION, A NITROGEN MONOXIDE PRODUCTION INHIBITION, AND A TRANSCRIPTION FACTOR NF KAPPA B SUPRESSING AGENT | SHIONOGI & CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20030125364-A1 | Antirheumatic agent | MATSUMOTO SAICHI (JP) | 2003-07-03 | — | — | US | disclosed |
| US-6525081-B1 | Inhibiting osteoclast formation and nitrogen monoxide production; suppressing transcription factor NF kappa B | SHIONOGI & CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| EP-1026162-A1 | ANTIRHEUMATIC | SHIONOGI & CO., LTD. (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015645-A1 | SUBSTITUTED PYRAN DERIVATIVES | SLC18A2, SLC6A4, SLC6A3 | AKR1B1 620/4885CA2 4594/4885GABRA1 1769/4885 |
| US-20140309427-A1 | Substituted Pyran Derivatives | SLC18A2, SLC6A4, SLC6A3 | AKR1B1 620/4885CA2 4594/4885GABRA1 1769/4885 |
| US-20030125364-A1 | Antirheumatic agent | IL1A, IL1B, IL17A | AKR1B1 271/4885CA2 761/4885GABRA1 687/4885 |
| US-20230117370-A1 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | CYP2B6, TYR, CYP2D6 | AKR1B1 1363/4885CA2 3009/4885GABRA1 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.